The new negotiated Medicare drug prices, while projected to save the U.S. government $6 billion in 2026, remain at least twice as high as prices charged in four other high-income countries according to analysis by Reuters.
In the U.S., a 30-day supply of nine of the 10 negotiated drugs (not including Novolog insulin, which lacks comparable prices) will cost Medicare a total of $17,581 in 2026. Sweden’s health care system would pay only $6,725 for the same medicines. Some of the covered medications are up to five times as expensive in the U.S. than in the other countries studied. Read more here.
NCPA
